Belzupacap sarotalocan is a Recombinant Protein owned by Aura Biosciences, and is involved in 6 clinical trials, of which 1 was completed, 3 are ongoing, and 2 are planned.

AU-011 acts by generating a target protein in a sustained manner for long periods of time. It utilizes an HPV VLP to deliver a cell-killing laser-activated molecule selectively to cancer cells in the eye.

The revenue for Belzupacap sarotalocan is expected to reach a total of $266m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Belzupacap sarotalocan NPV Report.

Belzupacap sarotalocan is originated and owned by Aura Biosciences.

Belzupacap sarotalocan Overview

AU-011 is under development for the treatment of ocular melanoma (melanomas of the iris and the ciliary body), uveal and choroidal melanoma. It is administered as an intravitreal, suprachoroidal, intratumoral and intramural route. The therapeutic candidate is developed based on Nanosmart technology. The drug candidate is a VDC (virus like drug conjugate).

Aura Biosciences Overview

Aura Biosciences is working on a novel class of oncology targeted therapeutics that will provide considerable therapeutic benefit to a variety of cancer indications with a high unmet need. The company is headquartered in United States.

The operating loss of the company was US$35.3 million in FY2021, compared to an operating loss of US$22.2 million in FY2020. The net loss of the company was US$35.3 million in FY2021, compared to a net loss of US$22.2 million in FY2020.

Quick View – Belzupacap sarotalocan

Report Segments
  • Innovator
Drug Name
  • Belzupacap sarotalocan
Administration Pathway
  • Intraocular
  • Intratumor
  • Intravitreal
  • Parenteral
Therapeutic Areas
  • Oncology
  • Ophthalmology
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.